Trial Profile
A Phase I/II Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 Plus Trametinib in Subjects With Small Cell Lung Cancer and Ras-Mutated Solid Tumors
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 28 Jun 2023
Price :
$35
*
At a glance
- Drugs Molibresib (Primary) ; Trametinib (Primary)
- Indications Small cell lung cancer; Solid tumours
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 07 Dec 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 01 Sep 2017 New trial record